Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
That's because there is nothing to see..........
What's the story here, I don't see anything.
You still in? Check the massive bids stacked at .10. I grabbed starter today.
boooooooooooooooooooooom
ok mm's i will sell you my 2400 shares at bid this afternoon, you happy i lose 20 bucks, hope you are satisfied
please someone buy this please!!!!!!!!!!!!!!!!!!!!!!!!!!
AIDA MONSTER NEWS! COVID VACCINE WORK, FIRST UPDATE IN OVER 2 YEARS!
AIDA REVERSE MERGERCOMING!!!!!!!!!!!!!!!!!!!
Because they dont think or DD lol. I'm not here to bash! nice trade and hope you all make money
yes they did lol Good trading there.. but AIDA is completely dead. The one with the merger is ADIA.
$AIDA: Did they now ? Holy shit $0.15
This thing is something else
GO $AIDA
They are mistaken the ticker with ADIA... ADIA is the one with the merger. Some morons slapped the wrong ticker.
Only 27 million shares outstanding and someone is trying to buy 1 million of them in one transaction
Someone posted a million share bid at .06, so they were willing to spend $60000 on AIDA when it was already up 200%+
$AIDA: Woooooooahhhhhhhhhh............ whats going on.
This one and $MMTS today.............. looking super hot
Time to step in
GO $AIDA
Huge run today on heavy volume in AIDA and no one is here talking about it.
Hmmmm I messed up and Double posted I would like to know more on this stock though if anyone still has a bunch etc..
Are You still Watching this AIDA Stock Paper Profit??
WOW No posts here in like FOREVER Isnt that just Something else.. Just no Much out there on this stock..;-(
AIDA is is getting attension and momentum
Aida had a new job posting on their website (aidapharma.com) on 2/11/09. Not much new otherwise. It's an information vacuum.
Maybe they'll file their annual report with pinksheets.com .
QFA2008, have you heard anything about the company's plans? I know you've previously spoken with the company.
Yes. I sent an e-mail through Aida's website this morning to ask if they still were going to file on pinksheets. I've requested information before but never gotten a response. I'll post if I hear anything.
Statistically the stock of companies which stop filing tend to do very poorly, hence the massive drop in share price today. Aida's drop may or may not be justified. Hopefully they're being truthful with the financial reports and hopefully they're not going to rip off investors.
Obviously their financials are extremely out of line with the current stock price. At this price, the company could buy nearly all the outstanding shares with just what they earned last quarter. Of course they don't seem to be buying back shares either so that also probably says something.
Filed 15g today to stop
filing reports
MK
Yes, it looks like the income tax benefit was about $0.03/share out of the $0.08. Even discounting that, the earnings were really good.
I'm not sure what to think about the Rh-APO2L drug. Six months or so ago they said they would release the phase II results within a month. If they actually did release those results, I don't know where they are--I assumed it would be in a press release but that wasn't the case.
The quarterly report says that the R&D expense for the period was mainly for costs incurred for phase II of Rh-APO2L and preparation for phase III so that gives some indication to the situation there.
looooks goood. tax benefit contributes some of the net income. TRAIL phase III might come soon. go aida.
Quarterly report out today.
http://www.sec.gov/Archives/edgar/data/1220286/000107878208001646/aida10q093008.htm
Record revenues and earnings. Revenues of $11.9 million, earnings of $2.3 million, earnings per share of $0.08. That's organic growth with no unusual items. I don't know why this stock is only trading at $0.32 bid/$0.38 ask. It seems like the stock should be worth much, much more. I must be missing something.
They have around $30 million of short-term debt and maybe tightening credit might be an issue--I'm not sure. They had about the same amount of short-term debt last year at this time too and it didn't hurt them.
All and all, it was an extremely nice quarter and the coming fourth quarter has historically been better than the third quarter apparently as hospitals gear up for the Chinese New Year.
QFA2008, have you heard anything about the company lately? Right now the stock is either a really good deal or a really bad deal. I haven't heard anything bad but it almost seems like something bad must be lurking to have the stock drop like that. Have you heard anything?
Their website seems to have changed addresses a short while ago. It's now aidapharma.com and the old web address seems to be gone. No new news on the site since a job opening was listed almost a month ago.
The stock took quite a hit today.
Down $0.24 to close at $0.31. Hard to say if there was any reason for the drop or not.
On the company's website from two months ago, it sounds like China is trying to restrict antibiotics to slow the progression of drug-resistant bacteria. That's obviously a negative for the company. On the good side, there haven't been any defaults announced on any of the loans guaranteed by the company.
The revenues have been growing extremely nicely over the past several quarters. If history is any indication, the fourth quarter has been very strong and we're in the fourth quarter now so hopefully they're pulling in a lot of cash.
The stock took a massive hit when they filed the 8-K with the SEC in April regarding the $7M. It looks like it got another $0.25 hit to the share price based on the quarterly report. I don't see anything else adverse in the 10-Q that wasn't there last time.
From 8/19 10-Q:
The Phase I clinical trial of rh-Apo2l has been successfully completed and the Phase II clinical trial has been initiated.
net loss at $0.25 is a dangerous number for a penny stock. With net loss at $0.25, this stock's risk is too high even with current price $0.5. The mutual guarantee business is too risky now--at least 30% of small and medium size company were going bankrupt in Zhejiang recently.
Yes, they said they were compiling the Rh-APO2L phase II data back in April and were going to publish the results a month from then. It's been over three months since then.
I wonder what the issue is.
The R&D expenses were somewhat higher in the second quarter than the first quarter and the 10-Q says R&D for the three- and six-month periods mainly represents costs incurred for clinical trials of Rh-APO2L. That's after they announced in late April that they were compiling the phase II data. That might mean that it hasn't been abandoned.
As I know, the Rh-Apo2L Phase II has signed and Aida hold this good news not to publish. Why ?
Do they want to publish after Q2 or wait for Rh-Apo2L Phase III approved by SFDA ?
10Q out.
http://www.sec.gov/Archives/edgar/data/1220286/000107878208001163/aida063008q.htm
Significant increase in revenues this quarter. Both revenues and gross margins were the largest in the company's history. This was offset by the $7,045,123 payment to make good on Nanwang's loan default this past April and by a $1,032,141 payment to Jiangyin Hi-tech Development Co. for business development apparently through 2007.
I don't know whether to buy or sell. On one hand, the growth is phenominal. Barring any problems, it looks like an extremely good deal based on its current business. On the other hand, they seem to be in the nebulous business of making loan guarantees on the side which could be costly. The company even guarantees a loan of a company controlled by a director.
Now on this quarter there was a new liability for channel development which I don't remember ever seeing before. Hopefully that's only a one-time payment but these costs keep popping up.
That revenue and margin growth was amazing, though, especially for the second quarter. Had they not had those two expenses, earnings for the quarter would have been about $0.06 and the two historically good quarters are coming next.
I'll probably hold what I have. I think it's a good risk for the potential reward but I don't like the risk part. I'm guessing either they'll hit really big or loan defaults on loans they guarantee will have a domino effect. Unfortunately there's no way I can easily assess the risk of the loans guaranteed by the company to make a better judgement.
NT 10-Q filed.
"The Company has encountered a delay in assembling the information, in particular its financial statements for the quarter ended June 30, 2008, required to be included in its June 30, 2008 Form 10-Q Quarterly Report. The Company expects to file its June 30, 2008, Form 10-Q Quarterly Report with the U.S. Securities and Exchange Commission within 5 calendar days of the prescribed due date."
So it looks like Tuesday.
Thanks. The only big question I have is about the Jiangsu Institute--I'm curious as to whether Jiangsu provides cash or whether Aida has to pay a portion of Jiangsu's expenses and how much. Aida never mentioned anything about that in any of the press releases about Jiangsu but it's very important from a risk perspective.
Certainly you don't have to call and ask. The next quarterly report should give some insight into that answer. However, if you're going to call and ask questions, that's an answer I would like to hear.
You're welcome! You done great job here too!
I think Mr. Jiang(Aida's Department Chief of Investment and senior financial manager) can speak good English.
You can call him on 86-571-85802712.
He has meeting most of time and you need to try to call more times.
Maybe everyone here list all the questions you want to ask.
I collect all the questions, then I call him and post answer here.
It's good you can speak Chinese. I'm limited to whatever Chinese web pages I can run through an online translator.
You're a valuable resource. Thanks.
Not investor relations! I call the company directly, and they have phone number in 10K.
That's good to hear. Certainly it's better to get the report late than never. Did you contact investor relations? I never received a response when I e-mailed them.
Regarding printing the ask price, I'm guessing it's a shareholder. Some people believe painting the tape helps the stock price. In the end it doesn't matter--it's the company performance which ultimately determines where the stock price will go.
Yes, the company said they are waiting for a couple of experts to sign the document.
These experts went to US for the conference(any conference about Rh-Apo2L recently ?) and they may visit some countries on the trip back.
When all the experts signed, the result will be official published. Then Aida will apply phase 3 test.
It is about one month behind the schedule.
That's all I get from Aida.
Do you have any idea about who print the ask price by 100 shares, Market Maker ? Why are they doing that ?
Re:<"The results of Phase 2 clinical testing are going out soon.">
Have you heard anything new about the results?
They said they would release the results of Phase 2 Clinical Trial within the next month, that period has come to pass as of May 28th. It has been nearly a month since they were supposed to release the results.
We have all been told that if we don't have something positive to say then don't say anything at all. The way I see it, this seems to be the approach AIDA has taken as it pertains to the Phase 2 Clinical Trials.
Brad
The results of Phase 2 clinical testing are going out soon.
Followers
|
8
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
170
|
Created
|
12/26/07
|
Type
|
Free
|
Moderators |
This is the board for Aida Pharmaceuticals, a company based in Hangzhou, China. Aida's primary revenue-producing product is an antibiotic named Etimicin but Aida is currently developing other drugs as well. Earnings (late 2007) may be somewhat depressed as there is a new mandate in China which requires hospitals to purchase drugs only from pharmaceutical manufacturers and this has hurt results somewhat as distributors returned sales to Aida. Aida expects that this issue is resolved. Aida's earnings, similar to other Chinese pharmaceutical companies, appear to be highly seasonal with most of the revenues occuring during the fourth quarter.
Revenues/Earnings are as follows (some data is derived from other filings) ($):
Qtr: | Rev: | COGS: | Gr Pft | SG&A | Other | NI: | CompNI | Shs: | per sh. |
3Q05 | $6,249,343 | $1,543,179 | $4,706,164 | $3,210,978 | _ | $730,540 | $817,007 | 23,375,000 | $0.035 |
4Q05 | 8,445,457 | 4,163,018 | 4,282,439 | 4,903,129 | _ | -30,452 | -20,372 | 23,481,849 | -0.001 |
1Q06 | 5,331,827 | 2,983,114 | 2,348,713 | 2,327,879 | _ | 14,536 | 58,237 | 25,000,000 | 0.002 |
2Q06 | 7,284,888 | 3,579,700 | 3,705,188 | 2,803,043 | _ | 398,888 | 414,243 | 25,000,000 | 0.017 |
3Q06 | 7,023,891 | 3,103,516 | 3,920,375 | 2,481,226 | _ | 919,285 | 968,626 | 25,000,000 | 0.039 |
4Q06 | 10,002,497 | 4,414,710 | 5,587,787 | 3,688,802 | _ | 120,875 | 296,941 | 27,000,000 | 0.011 |
1Q07 | 5,296,176 | 2,972,516 | 2,323,660 | 2,164,150 | _ | -160,204 | 42,574 | 27,000,000 | 0.002 |
2Q07 | 6,419,476 | 3,605,286 | 2,814,190 | 1,965,568 | _ | -16,315 | 367,603 | 27,000,000 | 0.014 |
3Q07 | 7,373,770 | 3,557,685 | 3,816,085 | 2,379,034 | _ | 519,061 | 541,213 | 27,000,000 | 0.020 |
4Q07 | 10,114,364 | 4,375,195 | 5,739,169 | 2,454,876 | _ | 2,397,283 | 2,193,730 | 27,000,000 | 0.081 |
1Q08 | 7,652,017 | 3,700,057 | 3,951,960 | 2,984,642 | _ | -18,980 | 56,193 | 27,000,000 | 0.002 |
2Q08 | 10,899,924 | 4,731,941 | 6,167,983 | 4,211,180 | -8,077,264* | -6,771,364 | -6,960,862 | 27,000,000 | -0.26 |
3Q08 | 11,885,458 | 4,958,239 | 6,927,219 | 4,069,538 | _ | 2,289,681 | 2,361,682 | 27,000,000 | 0.08 |
* During the second quarter of 2008, a company called Nanwang Information Industry Group Co. defaulted on its loans. Aida was the guarantor of Nanwang's loan and had to repay around 50M RMB (about $7,000,000) to make good on Nanwang's default. This resulted in the extraordinary loss per share during the second quarter of 2008. In addition, $1,032,141 was paid out as a consulting fee for previous business development work.
Aida has also won several patent infringement suits against other Chinese companies which were counterfeiting Aida's products. This, combined with the Chinese government's mandate to only purchase pharmaceuticals directly from the manufacturers, could positively impact Aida's bottom line.
While the Etimicin sales seem promising, Aida Pharmaceuticals is really interesting because of the situation regarding their anti-cancer drug under development called Rh-Apo2L. This is being produced by subsidiary of Aida's called Shanghai Qiaer Bio-technology Co., Ltd which is 77.5% owned by Aida. The drug works by triggering apoptosis (programmed cell death) in cancer cells. Phase II testing has shown strong efficacy with fewer side effects than other anti-cancer drugs.
Despite the potential, the share price is possibly depressed since Rh-Apo2L is also being developed separately by Genentech and Amgen in the United States. The basis for Rh-Apo2L appears to be a public research paper published in the U.S.. In China, Qiaer (Aida) began work on the drug while in the U.S., Genentech and Amgen began work on the drug. Genentech and Amgen are obviously much bigger than Aida. Patent situations in China are fledgling and uncertain but this could certainly be an issue. Aida currently has patents on the drug in China while Genetech and Amgen undoubtedly have patents in the U.S.. If Genentech and Amgen feel they have claims over Aida's intellectual property, the dispute could hurt Aida.
The R&D landscape in China is that China can finish clinical trials much faster than the United States due to delays in the U.S. due to FDA approvals. This makes it seem probable that Aida will begin marketing the drug before Genentech and Amgen. Other issues are the lack of or reduced patent protection and enforcement. Chinese companies often manufacture U.S. drugs despite patent protection in the U.S.. Pfizer recently won a landmark suit in China against a Chinese company which was producing Viagra.
However, unlike the Pfizer case, theft of intellectual property doesn't seem to be the issue with Aida. Aida went through all the development of Rh-Apo2L themselves. While the Pfizer case was against a company which copied even the name "Viagra," Aida hasn't taken any intellectual property as far as is known. The coincidence of the name of the drug being co-developed, Rh-Apo2L (recombinant Apo2L), refers to the type of protein and not any trademarked name.
If all goes well with commercialization, the current share price is undoubtedly cheap. If commercialization doesn't go well, the company still has its profitable Etimicin sales as well as other drugs in the pipeline and this may limit the downside risk. Given the current profitable business and the large potential, Aida seems like a very attractive play.
Company's website: http://en.aidapharma.com
Press Releases (abbreviated from full press releases):
3/27/08 Aida Acquires High-Level Research Institute in China (Jiangsu Institute of Microbiology Co.) "The acquisition is expected to yield multiple new products for Aida, including several that are already in clinical trials by China's State Food and Drug Administration."
4/9/2008: Aida Pharmaceuticals, Inc. Announces New Antibiotic Drug Under Development "...its recently-acquired research institute in the Jiangsu Province, the Jiangsu Institute of Microbiology Co., Ltd or "JSIM", is developing a new wide-spectrum antibiotic, Wetimicin, in the People's Republic of China. Wetimicin is from the newest generation of amino-glycoside family of antibiotics and is being tested for the treatment of various inflammations, such as respiratory infection, urinogenital infection, soft skin tissue infection as well as infections from trauma and operations, etc. JSIM's scientists believe that it might be safer and more reliable for children and elderly patients than current drug offerings in the marketplace."
4/18/08 Aida Announces New Anti-Cancer Drug Under Development "...it is developing a potential cancer drug that seeks to trigger cell death in certain types of cancer. Vasostatin-Apo2L, a pre-clinical product being developed by Aida's Shanghai Qiaer subsidiary, is a recombinant fusion protein that integrates the function of extracted fragments of Vasostatin, an inhibitor of angiogenesis and tumor growth, with the function of Rh-Apo2L, which induces the apoptosis of cancer cells."
4/22/08 Aida Pharmaceuticals, Inc. Announces Availability of Downloadable Corporate Synopsis on its Website http://en.aidapharma.com
4/24/08: Aida Pharmaceuticals, Inc. Announces Completion of Research Institute Acquisition "...it has completed the acquisition of a controlling interest in Jiangsu Institute of Microbiology Co., Ltd. ("JSIM"), one of the leading microbiology research institutes in the People's Republic of China."
4/28/08 Aida Pharmaceuticals, Inc. Announces Update on Progress of Rh-Apo2L Testing "...the Company is compiling data for its Phase 2 testing results of Rh-Apo2L and expects to announce the findings within the next month. The Company previously announced that the target cancers for the drug have been determined and initial results are extremely positive."
12/03/08 Aida Pharmaceutials files 15-12G, certification of notices of termination of registration, with the SEC. This will mean that Aida's shares will move to the pink sheets.
Moderating policy: All positive and negative opinions alike will be allowed and even occasional digressions (within reason) will be allowed. 'Moderating' will be kept to a minimum. The philosophy behind this is that some conflict and differing opinions is normal, that readers can form their own opinions from what they read and that readers usually don't need to be protected from posts by a moderator. Adverse opinions or misinformation can be refuted by other posters. If you feel this policy is inadequate or if you feel you are vulnerable to what others may say, it may be advisable for you to avoid this board. In addition, this board is no substitute for due diligence.
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |